Bio-Techne Corporation
$72.67-$0.03 (0.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $8.3B
- P/E
- 113.5x
- EV / EBITDA
- 39.7x
- Revenue
- $1.2B
- Net margin
- 6.0%
- ROCE
- 4.7%
Price chart
Technical chartScreen technicals →+23.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +0.1%
- 3M
- +0.5%
- 6M
- +55.6%
- 1Y
- +23.7%
- 5Y
- -42.0%
52-week range
Day change -$0.03 (0.0%) from $73 to $73 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in TECH, bought on each weekday since 2021.
News & filings
What Bio-Techne filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernNet profit fell 35.4% a year over three years.
Strengths (1)
- Free cash flow was 3.50 times net profit in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Read moreShow less
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Shares outstanding
- 155.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $8.3B
- P/E
- 113.5x
- P/B
- 4.3x
- EV / EBITDA
- 39.7x
- EV / Sales
- 7.1x
- P/S
- 6.8x
- 52-week high
- $72.84
- 52-week low
- $43.30
Profitability
- Operating margin
- 19.9%
- Net margin
- 6.0%
- EBITDA margin
- 17.8%
- ROE
- 3.8%
- ROCE
- 4.7%
- ROA
- 2.9%
- Asset turnover
- 0.48
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 5.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 3.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -56.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $256.6M
Solvency
- Current ratio
- 3.46
- Debt / Equity
- 0.23
- Debt / Assets
- 0.17
- CFO / Net profit
- 3.92
- Cash / Market cap
- 1.9%
Where the revenue went
Of every $100 of FY2025 revenue, $6 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $429.4M |
| Revenue | Gross profit | $790.3M |
| Gross profit | Research and development | $99.5M |
| Gross profit | Selling, general and administrative | $415.1M |
| Gross profit | Other operating expenses | $32.9M |
| Gross profit | Operating income | $242.8M |
| Operating income | Pretax income | $98.5M |
| Operating income | Interest and other expense | $144.3M |
| Pretax income | Tax and other | $25.1M |
| Pretax income | Net income | $73.4M |
Revenue and net profit
Revenue grew 5.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $1.1B | $272.1M |
| FY2023 | $1.1B | $285.3M |
| FY2024 | $1.2B | $168.1M |
| FY2025 | $1.2B | $73.4M |
Cash flows
FY2025: $287.6M from operations, $256.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $325.3M | $280.4M |
| FY2023 | $254.4M | $216.1M |
| FY2024 | $299.0M | $236.1M |
| FY2025 | $287.6M | $256.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.2B+5.2%1Y
- EBITDA
- $216.9M-30.7%1Y
- Net profit
- $73.4M-56.3%1Y
- Cash from operations
- $287.6M-3.8%1Y
- Free cash flow
- $256.6M+8.7%1Y
- Revenue CAGR, 3Y
- 3.3%
- Net profit CAGR, 3Y
- -35.4%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.2B | $216.9M | $73.4M | $256.6M | 3.8% | +5.2% | -56.3% |
Monthly returns
Month-by-month returns of TECH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.6B |
| Current assets | $608.3M |
| Non-current assets | $1.9B |
| Liabilities | $639.1M |
| Current liabilities | $175.8M |
| Non-current liabilities | $463.2M |
| Equity | $1.9B |
| Paid-in capital | $911.1M |
| Retained earnings | $1.1B |
| Minority interest | $0.00 |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; TECH highlighted.
P/E against peers
TECH trades at 113.5x earnings against a peer median of 21.8x (a 420% premium).
Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc., Glaukos Corporation, Protagonist Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Bio-Techne CorporationTECHthis companyP/E ↑ premium | $8.3B | 113.5x | 4.3x | 3.8% | 39.7x |
| Baxter International Inc.BAX | $10.0B | -10.4x | 1.6x | -15.6% | 23.2x |
| Krystal Biotech, Inc.KRYS | $9.1B | 44.3x | 7.4x | 16.8% | 51.2x |
| Charles River Laboratories International, Inc.CRL | $8.9B | — | 2.8x | -4.6% | 27.5x |
| Henry Schein, Inc.HSIC | $8.7B | 21.8x | 2.7x | 12.3% | 12.4x |
| Corcept Therapeutics IncorporatedCORT | $8.0B | 80.7x | 12.4x | 15.4% | 66.1x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Protagonist Therapeutics, Inc.PTGX | $6.6B | -50.8x | 10.8x | -21.2% | -41.4x |
| Peer median | — | 21.8x | 5.7x | 3.9% | 22.1x |
Year-to-date ROI
TECH since 1 January, against earlier years.
Historical volatility
TECH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 26.8% |
| FY2023 | 25.6% |
| FY2024 | 21.3% |
| FY2025 | 19.9% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.2B |
| Cost of revenueCost Of Revenue | $429.4M |
| Gross profitGross Profit | $790.3M |
| Operating expensesOperating Expense | $547.5M |
| Research and developmentResearch And Development | $99.5M |
| Selling, general and administrativeSelling General And Administration | $415.1M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $31.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $31.3M |
| Amortization | $31.3M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $31.3M |
| Total expensesTotal Expenses | $976.8M |
| Operating incomeOperating Income | $242.8M |
| Interest and other | |
| Pretax incomePretax Income | $98.5M |
| TaxTax Provision | $25.1M |
| Net incomeNet Income | $73.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.6B |
| Current assetsCurrent Assets | $608.3M |
| Non-current assetsTotal Non Current Assets | $1.9B |
| LiabilitiesTotal Liabilities Net Minority Interest | $639.1M |
| Current liabilitiesCurrent Liabilities | $175.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $463.2M |
| EquityTotal Equity Gross Minority Interest | $1.9B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $287.6M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $287.6M |
| Net income, continuing operationsNet Income From Continuing Operations | $73.4M |
| Depreciation and amortisationDepreciation And Amortization | $109.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $109.9M |
| Stock-based compensationStock Based Compensation | $40.8M |
| Deferred taxDeferred Tax | -$51.1M |
| Deferred income taxDeferred Income Tax | -$51.1M |
| Operating gains and lossesOperating Gains Losses | -$940.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | $0.00 |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | -$940.0k |
| Asset impairmentAsset Impairment Charge | $101.8M |
| Change in working capitalChange In Working Capital | $11.5M |
| Other non-cash itemsOther Non Cash Items | $2.1M |
| Investing cash flowInvesting Cash Flow | -$35.2M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$35.2M |
| Capital expenditureCapital Expenditure | -$31.0M |
| Purchase of PP&EPurchase Of PPE | -$31.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$31.0M |
| AcquisitionsPurchase Of Business | -$15.0M |
| DisposalsSale Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$15.0M |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $1.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | $1.1M |
| Dividends received (investing)Dividends Received Cfi | $7.3M |
| Other investing changesNet Other Investing Changes | $2.5M |
| Financing cash flowFinancing Cash Flow | -$253.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$253.9M |
| Debt issuedIssuance Of Debt | $104.0M |
| Debt repaidRepayment Of Debt | -$77.0M |
| Net debt issuedNet Issuance Payments Of Debt | $27.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $104.0M |
| Long-term debt repaidLong Term Debt Payments | -$77.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $27.0M |
| Net common stock issuedNet Common Stock Issuance | -$275.7M |
| Common stock repurchasedCommon Stock Payments | -$275.7M |
| Share buybacksRepurchase Of Capital Stock | -$275.7M |
| Stock options exercisedProceeds From Stock Option Exercised | $51.7M |
| Dividends paidCash Dividends Paid | -$50.4M |
| Common dividends paidCommon Stock Dividend Paid | -$50.4M |
| Other financing chargesNet Other Financing Charges | -$6.5M |
| Change in cashChanges In Cash | -$1.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 1,193.0% |
| Cash at the start of the yearBeginning Cash Position | $151.8M |
| Cash at the end of the yearEnd Cash Position | $162.2M |
| Free cash flowFree Cash Flow | $256.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Bio-Techne Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 113.5, learn when high multiples are justified.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read